The drug Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor (GLP1-R) agonist used for the treatment of T2DM and obesity [110]. This evidence concerns the gene GIP and obesity disorder.